MORE PATIENTS ACROSS ENGLAND AND WALES ARE SET TO BECOME ELIGIBLE FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Contributed by: AstraZeneca

Tags

AstraZeneca
Kidney disease

More Like This

NEW UK MODELLING DATA HIGHLIGHT POTENTIAL SOCIETAL, ECONOMIC AND ENVIRONMENTAL BENEFITS OF EARLY CHRONIC KIDNEY DISEASE INTERVENTION

PR Newswire associated0

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Business Wire logo

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

PR Newswire associated0

New Kidney Health Alliance Elevates Chronic Kidney Disease on Global Health Agenda